Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair

Phase 1 Completed 22 enrolled Pamela Munster Clovis Oncology, Inc. · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is an open label, non-randomized, dose escalation and expansion Phase Ib trial to evaluate the safety and recommended phase II dose of the combination of irinotecan and rucaparib.

Timeline

Start: 2018-01-12
Primary completion: 2021-03-01
Completion: 2021-03-01

Publications

Tsang ES, Dhawan MS, Pacaud R, Thomas S, Grabowsky J, Wilch L, Karipineni S, Kelley RK, Ko AH, Collisson E, Chapman JS, Ueda S, Bergsland EK, Munster P. Synthetic Lethality Beyond BRCA: A Phase I Study of Rucaparib and Irinotecan in Metastatic Solid Tumors With Homologous Recombination-Deficiency Mutations Beyond BRCA1/2. JCO Precis Oncol. 2024 Jun;8:e2300494. doi: 10.1200/PO.23.00494.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Irinotecan	Small molecule	40 mg/m2	Intravenous
Subject	Irinotecan	Small molecule	65 mg/m2	Intravenous
Subject	Irinotecan	Small molecule	100 mg/m2	Intravenous
Subject	Irinotecan	Small molecule	150 mg/m2	Intravenous
Subject	Rucaparib	Small molecule	300 mg	Oral
Subject	Rucaparib	Small molecule	400 mg	Oral
Subject	Rucaparib	Small molecule	600 mg	Oral

Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair

Summary

Timeline

Publications

Drugs

Indications